Predictive Technology Group (PRED) Appoints John C. Nelson, M.D., M.P.H. to the Predictive Technology Group Scientific Advisory Board

SALT LAKE CITY, Jan. 11, 2018 -- Predictive Technology Group, Inc. (OTCPINK:PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group Scientific Advisory Board.  Dr. Nelson, an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine.

Predictive Technology Group, Inc. (OTCPINK: PRED) announces that Dr. John C. Nelson, M.D., M.P.H. will join the Predictive Technology Group Scientific Advisory Board. Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine, www.predictivetechnologygroup.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/90c41a92-58f7-4099-a391-1f181c3e251e

Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society, and the Utah Medical Association.  Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ).  As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC.

Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education.  As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association.

Dr. Nelson’s civic involvement includes time on the advisory committee of the local Boys and Girls Club of Salt Lake City, the Christmas Box House board, and the board of Operation Kids.

As PRED continues to advance its growth, Dr. Nelson’s vast medical, scientific, and business knowledge and experience brings a valued addition to the Company’s advisory team.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (OTCPINK:PRED), a Salt Lake City, UT based Life-Sciences Holding company formed in 2013, aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics, and companion therapeutics through its wholly owned subsidiaries Predictive Therapeutics and Predictive Biotech. Its subsidiary companies currently focus on four main categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Tissue Products. PRED continues to explore the possibilities for additional disease identification and treatment categories in its integrated, registered laboratories. PRED subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively; www.predictivetechnologygroup.com, www.predrx.com and www.predbiotech.com.

For more information about Predictive Technology Group, Inc. and the release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and [email protected].

Forward-Looking Statements - To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Contact:
Rich Kaiser
Investor Relations
757-306-6090